Table 1.
Baseline characteristics.
| Characteristics | Total (n = 34) |
|---|---|
| Median age, years (range) | 6 (1–18) |
| Sex | |
| Female | 15 (44.1) |
| Male | 19 (55.9) |
| Reasons for enrollment | |
| Relapse | 18 (52.9) |
| Progressive disease | 6 (17.6) |
| Refractory | 10 (29.4) |
| Diagnosis | |
| Rhabdomyosarcoma | 24 (70.6) |
| Ewing’s sarcoma | 4 (11.8) |
| Wilms tumor | 2 (5.9) |
| Osteosarcoma | 1 (2.9) |
| Embryonal sarcoma | 1 (2.9) |
| Epithelioid sarcoma | 1 (2.9) |
| Malignant rhabdoid tumor of soft tissues | 1 (2.9) |
| Previous chemotherapy | 34 (100) |
| Median lines (range) | 2 (1–5) |
| 1 | 14 (41.2) |
| 2 | 6 (17.6) |
| ≥3 | 14 (41.2) |
| Median cycles (range) | 10 (2–25) |
| Prior anthracycline-based chemotherapy | 29 (85.3) |
| Median cycles (range) | 4 (1–7) |
| Prior cyclophosphamide-based chemotherapy | 31 (91.2) |
| Median cycles (range) | 4 (1–21) |
| Median cumulative dose of cyclophosphamide, g/m2 (range) | 9.6 (1.5–33.4) |
| Prior VCR + THP + CTX regimen | 21 (61.8) |
| Median cycles (range) | 4 (1–7) |
| Prior pirarubicin | 24 (70.6) |
| Median cumulative dose, mg/m2 (range) | 200 (50–360) |
| Prior doxorubicin | 5 (14.7) |
| Median cumulative dose, mg/m2 (range) | 250 (200–300) |
VCR, vincristine; THP, pirarubicin; CTX, cyclophosphamide.
Data are n (%), unless otherwise specified.